Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease

Journal: Nature Neuroscience

Published: 2018-09-17

DOI: 10.1038/s41593-018-0223-0

Affiliations: 18

Authors: 22

Go to article
Institutions FC
Brigham and Women's Hospital (BWH), United States of America (USA) 0.30
German Center for Neurodegenerative Diseases within the Helmholtz Association (DZNE), Germany 0.14
Institute of Cancer and Genomic Sciences, UB, United Kingdom (UK) 0.09
Neuroscience Division, Garvan Institute of Medical Research, Australia 0.06
St Vincent's Clinical School (STVCS), UNSW, Australia 0.06
Mayo Clinic Department of Neurology, United States of America (USA) 0.05
McLean Hospital, United States of America (USA) 0.05
Centre for Brain Research, The University of Auckland, New Zealand 0.05
C. S. Kubik Laboratory for Neuropathology, MGH, United States of America (USA) 0.05
UK Sanders-Brown Center on Aging (SBCoA), United States of America (USA) 0.05
Banner Sun Health Research Institute, United States of America (USA) 0.05
Department of Neurology, MGH, United States of America (USA) 0.02
State Key Laboratory of Bioelectronics, SEU, China 0.02
Sydney Medical School (SMS), USYD, Australia 0.01
Brain and Mind Centre, USYD, Australia 0.01
Ann Romney Center for Neurologic Diseases (CND), BWH, United States of America (USA) 0.01
Harvard Program in Neuroscience (PiN), United States of America (USA) 0.01

Return